Top

Published in:

01-08-2005 | Adis Drug Profile

Posaconazole

Author: Gillian M. Keating

Published in: Drugs | Issue 11/2005

Abstract

▴ Posaconazole is a triazole antifungal agent, administered as an oral suspension, with an extended spectrum of in vitro activity.

▴ Posaconazole 800 mg/day demonstrated clinically relevant activity against a range of fungi in patients with invasive fungal infections who were refractory to, or intolerant of, other antifungal therapy in an open-label, multicentre, phase III study (330 patients received posaconazole and 279 patients served as external controls).

▴ In aspergillosis, the global response success rate at the end-of-therapy visit (primary endpoint) was significantly higher in posaconazole recipients than in external controls (42% vs 26%).

▴ Posaconazole was also associated with overall success rates of 54% in zygomycosis, 46% in fusariosis, 43% in Pseudallescheria infection, 80% in phaeohyphomycosis and 100% in histoplasmosis. Success rates were 48% in refractory candidiasis, 69% in refractory coccidioidomycosis, 48% in refractory cryptococcal infection and 82% in refractory chromoblastomycosis or mycetoma.

▴ Posaconazole also demonstrated potential in febrile neutropenia in an open-label phase II study (success rate of 81% 7 days after the end of treatment).

▴ In a noncomparative, multicentre, phase III study in patients with advanced HIV infection who had azole-refractory oropharyngeal and/or oesophageal candidiasis, posaconazole 400 or 800 mg/day resulted in a clinical response in 132 of 176 patients (75%).

▴ Oral posaconazole suspension was generally well tolerated in patients with invasive fungal infections, including patients who received treatment for ≥1 year.

The use of trade names is for product identification purposes only and does not imply endorsement.

Pfaller MA, Diekema DJ. Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus. J Clin Microbiol 2004 Oct; 42(10): 4419–31PubMedCrossRef

Kontoyiannis DP, Mantadakis E, Samonis G. Systemic mycoses in the immunocompromised host: an update in antifungal therapy. J Hosp Infect 2003; 53(4): 243–58PubMedCrossRef

Mann PA, Patel R, Chen G, et al. Posaconazole is a potent inhibitor of sterol 14a-demethylation in zygomycetes [abstract no. M-1978 plus poster]. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2004 Oct 30–Nov 2; Washington, DC

Sabatelli FJ, Loebenberg D, Mendrick CA, et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against approximately 18,000 strains of clinically significant yeasts and moulds [abstract no. M-1810 plus poster]. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2004 Oct 30–Nov 2; Washington, DC

Sabatelli F. In vitro and in vivo interaction of posaconazole (POS) and caspofungin (CSP) against Aspergillus [abstract no. M-990 plus poster]. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003 Sep 14–17; Chicago

Oliveira ER, Fothergill AW, Kirkpatrick WR, et al. In vitro interaction of posaconazole and caspofungin against Candida glabrata [poster]. Focus on Fungal Infections 14; 2004 Mar 24–26; New Orleans

Munayyer HK, Mann PA, Chau AS, et al. Posaconazole is a potent inhibitor of sterol 14α-demethylation in yeasts and molds. Antimicrob Agents Chemother 2004 Oct; 48(10): 3690–6PubMedCrossRef

Xiao L, Madison V, Chau AS, et al. Three-dimensional models of wild-type and mutated forms of cytochrome P450 14α-sterol demethylases from Aspergillus fumigatus and Candida albicans provide insights into posaconazole binding. Antimicrob Agents Chemother 2004 Feb; 48(2): 568–74PubMedCrossRef

Paphitou NI, Ostrosky-Zeichner L, Paetznick VL, et al. In vitro antifungal susceptibilities of Trichosporon species. Antimicrob Agents Chemother 2002 Apr; 46(4): 1144–6PubMedCrossRef

10.

Sugar AM, Liu X-P. In vitro and in vivo activities of SCH 56592 against Blastomyces dermatitidis. Antimicrob Agents Chemother 1996 May; 40(5): 1314–6PubMed

11.

Perfect JR, Cox GM, Dodge RK, et al. In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans. Antimicrob Agents Chemother 1996 Aug; 40(8): 1910–3PubMed

12.

Espinel-Ingroff A. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol 1998 Oct; 36(10): 2950–6PubMed

13.

Diekema DJ, Messer SA, Hollis RJ, et al. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J Clin Microbiol 2003 Aug; 41(8): 3623–6PubMedCrossRef

14.

Pfaller MA, Messer SA, Hollis RJ, et al. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob Agents Chemother 2002 Apr; 46(4): 1032–7

15.

Pfaller MA, Messer SA, Boyken L, et al. In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program. Diagn Microbiol Infect Dis 2004 Mar; 48(3): 201–5

16.

Pfaller MA, Messer SA, Hollis RJ, et al. In vitro activities of posaconazole (Sch 56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformans. Antimicrob Agents Chemother 2001 Oct; 45(10): 2862–4CrossRef

17.

Laverdiere M, Hoban D, Restieri C, et al. In vitro activity of three new triazoles and one echinocandin against Candida bloodstream isolates from cancer patients. J Antimicrob Chemother 2002 Jul; 50(1): 119–23PubMedCrossRef

18.

Li X, Brown N, Chau AS, et al. Changes in susceptibility to posaconazole in clinical isolates of Candida albicans. J Antimicrob Chemother 2004 Jan; 53(1): 74–80PubMedCrossRef

19.

Mann PA, Parmegiani RM, Wei S-Q, et al. Mutations in Aspergillus fumigatus resulting in reduced susceptibility to posaconazole appear to be restricted to a single amino acid in the cytochrome P450 14α-demethylase. Antimicrob Agents Chemother 2003 Feb; 47(2): 577–81PubMedCrossRef

20.

Manavathu EK, Cutright JL, Loebenberg D, et al. A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592). J Antimicrob Chemother 2000 Aug; 46: 229–34PubMed

21.

Manavathu EK, Ramesh MS, Baskaran I, et al. A comparative study of the post-antifungal effect (PAFE) of amphotericin B, triazoles and echinocandins on Aspergillus fumigatus and Candida albicans. J Antimicrob Chemother 2004 Feb; 53(2): 386–9PubMedCrossRef

22.

Mosquera J, Denning DW. Azole cross-resistance in Aspergillus fumigatus. Antimicrob Agents Chemother 2002 Feb; 46(2): 556–7PubMedCrossRef

23.

Manavathu EK, Abraham OC, Chandrasekar PH. Isolation and in vitro susceptibility to amphotericin B, itraconazole and posaconazole of voriconazole-resistant laboratory isolates of Aspergillus fumigatus. Clin Microbiol Infect 2001 Mar; 7(3): 130–7PubMedCrossRef

24.

Cacciapuoti A, Loebenberg D, Corcoran E, et al. In vitro and in vivo activities of SCH 56592 (posaconazole), a new triazole antifungal agent, against Aspergillus and Candida. Antimicrob Agents Chemother 2000 Aug; 44(8): 2017–22PubMedCrossRef

25.

Dromer F, Improvisi L, Dupont B, et al. In vitro and in vivo activity of SCH-56592 (posaconazole) against Aspergillus fumigatus. J Mycol Med 2002 Jun; 12: 52–7

26.

Graybill JR, Hernandez S, Bocanegra R, et al. Antifungal therapy of murine Aspergillus terreus infection. Antimicrob Agents Chemother 2004 Oct; 48(10): 3715–9PubMedCrossRef

27.

Kirkpatrick WR, McAtee RK, Fothergill AW, et al. Efficacy of SCH56592 in a rabbit model of invasive asperigillosis. Antimicrob Agents Chemother 2000 Mar; 44(3): 780–2PubMedCrossRef

28.

Oakley KL, Morrissey G, Denning DW. Efficacy of SCH-56592 in a temporarily neutropenic murine model of invasive asper-gillosis with an itraconazole-susceptible and an itraconazole-resistant isolate of Aspergillus fumigatus. Antimicrob Agents Chemother 1997 Jul; 41(7): 1504–7PubMed

29.

Graybill JR, Bocanegra R, Najvar LK, et al. SCH56592 treatment of murine invasive aspergillosis. J Antimicrob Chemother 1998 Oct; 42: 539–42PubMedCrossRef

30.

Walsh TJ, Petraitis V, Petraitiene R, et al. Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B. J Infect Dis 2003 Jul 15; 188(2): 305–19PubMedCrossRef

31.

Imai JK, Singh G, Clemons KV, et al. Efficacy of posaconazole in a murine model of central nervous system aspergillosis. Antimicrob Agents Chemother 2004 Oct; 48(10): 4063–6PubMedCrossRef

32.

Petraitiene R, Petraitis V, Groll AH, et al. Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia. Antimicrob Agents Chemother 2001 Mar; 45(3): 857–69PubMedCrossRef

33.

Lozano-Chiu M, Arikan S, Paetznick VL, et al. Treatment of murine fusariosis with SCH 56592. Antimicrob Agents Chemother 1999 Mar; 43(3): 589–91PubMed

34.

Connolly P, Wheat J, Schnizlein-Bick C, et al. Comparison of a new triazole antifungal agent, Schering 56592, with itraconazole and amphotericin B for treatment of histoplasmosis in immunocompetent mice. Antimicrob Agents Chemother 1999 Feb; 43(2): 322–8PubMed

35.

Connolly P, Wheat LJ, Schnizlein-Bick C, et al. Comparison of a new triazole, posaconazole, with itraconazole and amphotericin B for treatment of histoplasmosis following pulmonary challenge in immunocompromised mice. Antimicrob Agents Chemother 2000 Oct; 44(10): 2604–8PubMedCrossRef

36.

Andes D, Marchillo K, Conklin R, et al. Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis. Antimicrob Agents Chemother 2004 Jan; 48(1): 137–42PubMedCrossRef

37.

Al-Abdely HM, Najvar L, Bocanegra R, et al. SCH 56592, amphotericin B, or itraconazole therapy of experimental murine cerebral phaeohyphomycosis due to Ramichloridium obovoideum (Ramichloridium mackenziei). Antimicrob Agents Chemother 2000 May; 44(5): 1159–62PubMedCrossRef

38.

Graybill JR, Najvar LK, Johnson E, et al. Posaconazole therapy of disseminated phaeohyphomycosis in a murine model. Antimicrob Agents Chemother 2004 Jun; 48(6): 2288–91PubMedCrossRef

39.

Barchiesi F, Schimizzi AM, Caselli F, et al. Activity of the new antifungal triazole, posaconazole, against Cryptococcus neoformans. J Antimicrob Chemother 2001 Dec; 48: 769–73PubMedCrossRef

40.

González GM, Tijerina R, Najvar LK, et al. Activity of posaconazole against Pseudallescheria boydii: in vitro and in vivo assays. Antimicrob Agents Chemother 2003 Apr; 47(4): 1436–8PubMedCrossRef

41.

González GM, Tijerina R, Najvar LK, et al. In vitro and in vivo activities of posaconazole against Coccidioides immitis. Antimicrob Agents Chemother 2002 May; 46(5): 1352–6PubMedCrossRef

42.

Lutz JE, Clemons KV, Aristizabal BH, et al. Activity of the triazole SCH 56592 against disseminated murine coccidioido-mycosis. Antimicrob Agents Chemother 1997 Jul; 41(7): 1558–61PubMed

43.

Sun QN, Najvar LK, Bocanegra R, et al. In vivo activity of posaconazole against Mucor spp. in an immunosuppressed-mouse model. Antimicrob Agents Chemother 2002 Jul; 46(7): 2310–2CrossRef

44.

Dannaoui E, Meis JFGM, Loebenberg D, et al. Activity of posaconazole in treatment of experimental disseminated zygo-mycosis. Antimicrob Agents Chemother 2003 Nov; 47(11): 3647–50PubMedCrossRef

45.

Najvar LK, Cacciapuoti A, Hernandez S, et al. Activity of posaconazole combined with amphotericin B against Aspergillus flavus infection in mice: comparative studies in two laboratories. Antimicrob Agents Chemother 2004 Mar; 48(3): 758–64PubMedCrossRef

46.

Barchiesi F, Spreghini E, Schimizzi AM, et al. Posaconazole and amphotericin B combination therapy against Cryptococcus neoformans infection. Antimicrob Agents Chemother 2004 Sep; 48(9): 3312–6PubMedCrossRef

47.

Cacciapuoti A, Gurnani M, Halpern J, et al. Interaction between posaconazole and amphotericin B in concomitant treatment against Candida albicans in vivo. Antimicrob Agents Chemother 2005 Feb; 49(2): 638–42PubMedCrossRef

48.

Courtney R, Pai S, Laughlin M, et al. Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob Agents Chemother 2003 Sep; 47(9): 2788–95PubMedCrossRef

49.

Ezzet F, Wexler D, Courtney R, et al. Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations. Clin Pharmacokinet 2005; 44(2): 211–20PubMedCrossRef

50.

Courtney R, Wexler D, Radwanski E, et al. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br J Clin Pharmacol 2004 Feb; 57(2): 218–22PubMedCrossRef

51.

Krieter P, Flannery B, Musick T, et al. Disposition of posaconazole following single-dose oral administration in healthy subjects. Antimicrob Agents Chemother 2004 Sep; 48(9): 3543–51PubMedCrossRef

52.

Courtney R, Sansone A, Statkevich P, et al. Effect of age and gender on the pharmacokinetics of posaconazole in healthy volunteers [abstract no. A-1563 plus poster]. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003 Sep 14–17; Chicago

53.

Courtney R, Sansone A, Kantesaria B, et al. Effect of ethnicity on the pharmacokinetics of posaconazole in healthy volunteers [abstract no. A-1564 plus poster]. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003 Sep 14–17; Chicago

54.

Wexler D, Courtney R, Richards W, et al. Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study. Eur J Pharm Sci 2004 Apr; 21(5): 645–53PubMedCrossRef

55.

Sansone A, Belle D, Statkevich P, et al. Effect of posaconazole on the pharmacokinetics of tacrolimus in healthy volunteers [abstract no. A-1603 plus poster]. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003 Sep 14-17; Chicago

56.

Courtney RD, Statkevich P, Laughlin M, et al. Potential for a drug interaction between posaconazole and phenytoin [abstract no. A-28]. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2001 Sep 22–25; Chicago

57.

Courtney RD, Statkevich P, Laughlin M, et al. Potential for a drug interaction between posaconazole and rifabutin [abstract no. A-29]. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2001 Sep 22–25; Chicago

58.

Courtney R, Wexler D, Statkevich P, et al. Effect of cimetidine on the pharmacokinetics of posaconazole in healthy volunteers [abstract no. A-1838]. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002 Sep 27–30; San Diego

59.

Courtney R, Sansone A, Statkevich P, et al. Assessment of the pharmacokinetic (PK), pharmacodynamic (PD) interaction potential between posaconazole and glipizide in healthy volunteers [abstract no. PII-63]. Clin Pharmacol Ther 2003 Feb; 73 (2): P45 plus poster presented at the 2003 Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics; 2003 Apr 2–5; Washington, DC

60.

Courtney R, Radwanski E, Lim J, et al. Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men. Antimicrob Agents Chemother 2004 Mar; 48(3): 804–8PubMedCrossRef

61.

Krishna G, Wexler D, Courtney R, et al. Posaconazole plasma concentrations in pediatric patients with invasive fungal infections [abstract no. A-41 plus poster]. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2004 Oct 30–Nov 2; Washington, DC

62.

Courtney R, Martinho M, Lim J, et al. Evaluation of the effect of age, weight, race, and gender on posaconazole plasma concentrations in HIV-infected patients [poster]. 13th European Congress of Clinical Microbiology and Infectious Diseases; 2003 May 10–13; Glasgow

63.

Courtney RD, Statkevich P, Laughlin M, et al. Effect of posaconazole on the pharmacokinetics of cyclosporine [abstract no. A-27]. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2001 Sep 22–25; Chicago

64.

Sansone A, Courtney R, Mellars L, et al. Posaconazole has no clinically significant effect on the QTc interval in healthy volunteers [abstract no. A-l 100 plus poster]. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2004 Oct 30–Nov 2; Washington, DC

65.

Courtney RD, Laughlin M, Gontz H, et al. Single-dose pharmacokinetics of posaconazole in subjects with various degrees of chronic liver disease [abstract]. Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists; 2000 Oct 29–Nov 2; Indianapolis

66.

Courtney R, Sansone A, Smith W, et al. Posaconazole pharmacokinetics, safety, and tolerability in subjects with varying degrees of chronic renal disease. J Clin Pharmacol 2005 Feb; 45(2): 185–92PubMedCrossRef

67.

Groll AH, Kolve H. Antifungal agents: in vitro susceptibility testing, pharmacodynamics, and prospects for combination therapy. Eur J Clin Microbiol Infect Dis 2004 Apr; 23(4): 256–70PubMedCrossRef

68.

Ghosal A, Hapangama N, Yuan Y, et al. Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of posaconazole (Noxafil). Drug Metab Dispos 2004 Feb; 32(2): 267–71PubMedCrossRef

69.

Data on file, Schering-Plough Research Institute, 2005.

70.

Raad I, Chapman S, Bradsher R, et al. Posaconazole (POS) salvage therapy for invasive fungal infections (IFI) [abstract no. M-669 and oral presentation]. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2004 Oct 30–Nov 2; Washington, DC

71.

Anstead G, Corcoran G, Lewis J, et al. Posaconazole therapy for coccidioidomycosis: a case series [abstract no. 143 plus poster]. 41st Annual Meeting of the Infectious Diseases Society of America; 2003 Oct 9–12; San Diego

72.

Corcoran G, Greenberg R, Herbrecht R, et al. Posaconazole therapy for refractory invasive zygomycosis [poster]. 10th Congress of the European Confederation of Medical Mycology; 2004 Jul 17–20; Wroclaw

73.

Restrepo A, Clark B, Graham D, et al. Treatment of histoplasmosis with posaconazole [abstract no. M-973 plus poster]. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003 Sep 14–17; Chicago

74.

Pitisuttithum P, Gaona-Flores V, Negroni R, et al. Efficacy of posaconazole (POS) in treatment of central nervous system (CNS) fungal infections: results of an open-label study [abstract no. M-978 plus poster]. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003 Sep 14–17; Chicago

75.

Hare R, Alexov M, Al-Abdely H, et al. Efficacy of posaconazole in the treatment of non-cryptococcal central nervous system fungal infections [poster]. 10th Congress of the European Confederation of Medical Mycology; 2004 Jul 17–20; Wroclaw

76.

Herbrecht R, Marr K, Catanzaro A, et al. Posaconazole (POS) as salvage therapy for invasive fungal infections (IFIs) unresponsive to voriconazole: a case series [abstract no. M-1044 and poster]. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2004 Oct 30–Nov 2; Washington, DC

77.

Negroni R, Tobon A, Bustamante A, et al. Posaconazole (POS) treatment of mycetoma and chromoblastomycosis [abstract no. M-976 plus poster]. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003 Sep 14–17; Chicago

78.

Perfect JR, Graham DR, Corcoran G, et al. Posaconazole (POS) safety and efficacy in elderly (≥65 years of age) patients with invasive fungal infections (IFIs) [poster]. 42nd Annual Meeting of the Infectious Diseases Society of America; 2004 Sep 30–Oct 3; Boston

79.

Raad I, Hachem R, Herbrecht R, et al. Experience of posaconazole in patients with fusariosis [poster]. 13th International Symposium on Infections in the Immunocompromised Host; 2004 Jul 10–14; Granada

80.

Ullmann AJ, Comely OA, Burchardt A, et al. Safety and efficacy of posaconazole (POS) in a pharmacokinetic study in patients with febrile neutropenia (FN) or refractory invasive fungal infections (rIFI) [abstract no. M-1257 plus poster]. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003 Sep 14–17; Chicago

81.

Segal BH, Barnhart LA, Anderson VL, et al. Posaconazole as salvage therapy in patients with chronic granulomatous disease and invasive filamentous fungal infection. Clin Infect Dis 2005 Jul 1; 40: 1684–8PubMedCrossRef

82.

Raad II, Boktour MR, Hanna HA, et al. Posaconazole (POS) compared to amphotericin B lipid formulations (AmB/LPD) in combination with caspofungin (CASP) as salvage therapy for invasive aspergillosis (IA) in patients (pts) with hematologic malignancy (HM) [abstract no. M-1035]. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2004 Oct 30–Nov 2; Washington, DC

83.

Walsh T, Patterson T, Langsten A, et al. Posaconazole for treatment of invasive aspergillosis in patients who are refractory to or intolerant of conventional therapy: an external controlled blinded trial [abstract no. 682]. Blood 2003 Nov 16; 102 (11 Pt 1): 195–6

84.

Garbino J, Uckay I, Puppo M, et al. Absidia spp posttraumatic infection recovery with posaconazole [poster]. 6th European Congress of Chemotherapy and Infection and the 24th Interdisciplinary Meeting on Chemotherapy and Infection; 2004 Dec 1–3; Paris

85.

Kuehnbach R, Muth A, Dellian M, et al. Successful treatment of rhinocerebral zygomycosis and pulmonary aspergillosis in a patient with thymic acute lymphoblastic leukemia [poster]. 6th European Congress of Chemotherapy and Infection; 2004 Dec 1–3; Paris

86.

Tissot-Dupont H, Branger S, Pham T, et al. Aspergillus flavus chondrocostal osteomyelitis treated with posaconazole: a case study [poster]. 9th Congress of the European Confederation of Medical Mycology and 7th Trends in Invasive Fungal Infections; 2003 Sep 28–Oct 1; Amsterdam

87.

Proia L. Efficacy of posaconazole for chronic refractory Alternaria infection [abstract no. P743]. 15th European Congress of Clinical Microbiology and Infectious Diseases; 2005 Apr 2–5; Copenhagen

88.

Anstead GM, Martinez M, Graybill JR. Control of Candida glabrata endovascular TIPS infection with posaconazole [poster]. 15th Congress of the International Society for Human and Animal Mycology; 2003 May 25–29; San Antonio

89.

Lewis JS, Anstead G, Graybill J. Successful treatment of disseminated coccidioidomycosis (Coccidioides immitis) with posaconazole, a new triazole (SCH 56592): a case report [poster]. 15th Congress of the International Society for Human and Animal Mycology; 2003 May 25–29; San Antonio

90.

Dheu C, Entz-Werle N, Campagni R, et al. Severe disseminated fusariosis in a leukemic child successfully treated with posaconazole and white blood cell transfusions [abstract no. P740]. 15th European Congress of Clinical Microbiology and Infectious Diseases; 2005 Apr 2–5; Copenhagen

91.

Bregenzer T. Posaconazole treatment in rhino-cerebro-ocular zygomycosis [poster]. 6th European Congress of Chemotherapy and Infection and the 24th Interdiscplinary Meeting on Chemotherapy and Infection; 2004 Dec 1–3; Paris

92.

Knapp K, Allison K, Franklin J. Successful combination therapy with posaconazole and amphotericin B for multifocal disseminated zygomycosis in a patient with relapsed acute lymphoblastic leukaemia [abstract no. P741]. 15th European Congress of Clinical Microbiology and Infectious Diseases; 2005 Apr 2–5; Copenhagen

93.

Dupont B, Weinbreck P, Brugiere O, et al. Effects of posaconazole salvage therapy in five patients wtih zygomycosis [abstract no. P742]. 15th European Congress of Clinical Microbiology and Infectious Diseases; 2005 Apr 2–5; Copenhagen

94.

Ullmann AJ, Hebart H, Einsele H, et al. Posaconazole in a patient with refractory Rhizopus spp. infection and relapsed acute myelogenous leukemia (AML) [poster]. 6th European Congress of Chemotherapy and Infection; 2004 Dec 1–3; Paris

95.

Herbrecht R, Letscher-Bru V, Fohrer C, et al. Acremonium strictum pulmonary infection in a leukemic patient successfully treated with posaconazole after failure of amphotericin B. Eur J Clin Microbiol Infect Dis 2002 Nov; 21(11): 814–7PubMedCrossRef

96.

Lodge BA, Ashley ED, Steele MP, et al. Aspergillus fumigatus empyema, arthritis, and calcaneal osteomyelitis in a lung transplant patient sucessfully treated with posaconazole. J Clin Microbiol 2004 Mar; 42(3): 1376–8PubMedCrossRef

97.

Negroni R, Helou SH, Petri N, et al. Case study: posaconazole treatment of disseminated phaeohyphomycosis due to Exophiala spinifera. Clin Infect Dis 2004 Feb 1; 38(3): el5–20CrossRef

98.

Herbrecht R, Kessler R, Kravanja C, et al. Successful treatment of Fusarium proliferatum pneumonia with posaconazole in a lung transplant recipient. J Heart Lung Transplant 2004 Dec; 23(12): 1451–4PubMedCrossRef

99.

Sponsel WE, Graybill JR, Nevarez HL, et al. Ocular and systemic posaconazole (SCH-56592) treatment of invasive Fusarium solani keratitis and endophthalmitis [letter]. Br J Ophthalmol 2002 Jul; 86(7): 829–30PubMedCrossRef

100.

Al-Abdely HM, Alkhunaizi AM, Al-Tawfiq JA, et al. Successful therapy of cerebral phaeohyphomycosis due to Ramichloridium mackenziei with the new triazole, posaconazole. Med Mycol 2005 Feb; 43(1): 91–5PubMedCrossRef

101.

Tobón AM, Arango M, Fernández D, et al. Mucormycosis (zygomycosis) in a heart-kidney transplant recipient: recovery after posaconazole therapy. Clin Infect Dis 2003 Jun 1; 36: 1488–91PubMedCrossRef

102.

Mellinghoff IK, Winston DJ, Mukwaya G, et al. Treatment of Scedosporium apiospermum brain abscesses with posaconazole. Clin Infect Dis 2002 Jun 15; 34(12): 1648–50PubMedCrossRef

103.

Skiest DJ, Vazquez JA, Graybill JR, et al. Open-label trial of posaconazole (POS) for azole-refractory oropharyngeal (OP) and esophageal (ES) candidiasis in HIV/AIDS patients: final analysis [abstract no. M-1027 plus poster]. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2004 Oct 30–Nov 2; Washington, DC

104.

Berg D, Graybill JR, Mendrick C, et al. Posaconazole treatment for refractory oropharyngeal candidiasis: a report of two cases [poster]. Focus on Fungal Infections 14; 2004 Mar 24–26; New Orleans

105.

Cornely OA, Fätkenheur G, Balke M, et al. Successful posaconazole treatment of chronic refractory oesophageal candidiasis in an AIDS patient: a case report [poster]. Focus on Fungal Infections 14; 2004 Mar 24–26; New Orleans

106.

Berg D, Graybill JR, McNicholas P, et al. Successful posaconazole treatment of chronic esophageal candidiasis with eosophageal stricture due to Candida glabrata and C. albicans: a case report [poster]. Focus on Fungal Infections 14; 2004 Mar 24–26; New Orleans

107.

Graybill JR, Raad I, Negroni R, et al. Posaconazole (POS) long-term safety in patients with invasive fungal infections (IFIs) [abstract no. M-1025 plus poster]. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2004 Oct 30–Nov 2; Washington, DC

108.

Sansone A, Courtney R, Brundage T, et al. Safety and tolerability of posaconazole (POS): evaluation of 18 controlled healthy volunteer (HV) studies [abstract no. A-1099 plus poster]. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2004 Oct 30–Nov 2; Washington, DC

Title: Posaconazole
Author: Gillian M. Keating
Publication date: 01-08-2005
Publisher: Springer International Publishing
Published in: Drugs / Issue 11/2005
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI: https://doi.org/10.2165/00003495-200565110-00007

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Posaconazole

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 11/2005

Pegaptanib

Pegaptanib in Exudative Age-Related Macular Degeneration

Posaconazole

Rosiglitazone/Metformin

Posaconazole

Impact of Smoking on Asthma Therapy